Emapalumab-lzsg - Biologic Drug Details

Summary for emapalumab-lzsg

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for emapalumab-lzsg

Mechanism of Action	Interferon gamma Antagonists
Established Pharmacologic Class	Interferon gamma Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for emapalumab-lzsg Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for emapalumab-lzsg Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for emapalumab-lzsg Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Emapalumab-lzsg

Last updated: March 4, 2026

What is emapalumab-lzsg, and what is its approved use?

Emapalumab-lzsg is a monoclonal antibody targeting interferon gamma (IFN-γ). It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in pediatric and adult patients who are refractory or intolerant to conventional therapy. The drug is marketed under the brand name Gamifant.

How does the market landscape for emapalumab-lzsg look?

The market for biologics in rare immune disorders is limited but high-value. Emapalumab operates within a niche segment, with limited competition due to the rarity of HLH. Currently, only a few drugs target HLH, with treatments typically revolving around immunosuppressants like corticosteroids, etoposide, and cyclosporine, which are non-specific and associated with high toxicity profiles.

Key competitors

• Etoposide (off-label for HLH)
• Corticosteroids
• Cyclosporine

There are no direct biologic competitors with the same mechanism of action in the market, which gives emapalumab-lzsg an early-mover advantage in this space.

What are the current market drivers?

1. Rare disease designation: HLH is a life-threatening condition with an incidence of approximately 1 in 50,000 live births and higher prevalence among children. This status provides incentives like orphan drug exclusivity, tax credits, and grant support.

2. Unmet medical need: Conventional therapies have high toxicity with limited efficacy; emapalumab addresses a specific pathogenic pathway, reducing side effects.

3. Regulatory support: Fast Track and Orphan Drug designations expedite development and approval, reducing costs and time to market.

4. Pricing potential: Organic to rare disease biologic pricing models, with list prices estimated between $200,000 to $350,000 annually per patient, depending on dosing and reimbursement negotiations.

Market size estimate

• Global HLH patient population: estimated between 1,200 and 2,500 cases annually, predominantly pediatric.
• Estimated U.S. market size: approximately 1,000 patients.
• Potential global market size (including Europe, Japan, and other markets): 2,000–3,500 patients.

How is the financial trajectory shaping?

Revenue projections

• Initial sales (2023-2025): Launch phase, with sales likely to total $50 million to $100 million globally by 2025, driven by early adoption in specialized centers.
• Mid-term growth (2026-2030): Expansion into additional indications like secondary HLH, macrophage activation syndrome (MAS), and other interferon gamma-driven diseases, potentially doubling or tripling revenue.
• Long-term outlook: If emapalumab-lzsg demonstrates safety and efficacy in broader indications, annual revenue could approach $500 million by 2030.

Cost considerations

• Biologics development costs are high, with R&D investments exceeding $200 million, including clinical trials and regulatory activities.
• Manufacturing costs are relatively stable but high, with unit costs around $10,000 to $30,000 per patient annually.
• Reimbursement negotiations will directly influence pricing and revenue, especially in major markets like the U.S. and Europe.

What factors could influence market penetration and growth?

• Regulatory approvals in other indications: Expansion into secondary HLH and related diseases.
• Reimbursement policies: Coverage and pricing negotiations influence patient access.
• Competitive landscape: Emerging therapies targeting interferon pathways or alternative immune modulators.
• Clinical research outcomes: Validation of efficacy and safety in broader populations.

How does pricing compare with similar biologics?

Drug	Indication	List Price (per year)	Patient Population	Market Dynamics
Emapalumab-lzsg (Gamifant)	HLH	$200,000 - $350,000	<2,000 globally	Orphan drug exclusivity, high unmet need
Etoposide	HLH (off-label)	N/A (generic)	N/A	Low cost, non-specific, high toxicity
Ruxolitinib (Jakafi)	Myelofibrosis, cytokine storms	~$160,000	Variable, wider population	Potential in cytokine-driven conditions

Key risks affecting financial trajectory

• Limited patient numbers constrain revenue growth.
• Reimbursement uncertainties threaten pricing power.
• Clinical trial failures or safety concerns could delay or diminish commercial prospects.
• Competition from novel therapies may erode market share.

Key Takeaways

• Emapalumab-lzsg fills a critical gap in HLH treatment, a rare, life-threatening disorder.
• Market size remains limited but high-value due to orphan designation and pricing.
• Revenue prospects hinge on expanding indications and market access.
• Development and manufacturing costs are significant, with high profit potential in favorable reimbursement environments.
• Long-term growth depends on clinical success, competitive dynamics, and regulatory approvals.

FAQs

1. What are the main barriers to market growth for emapalumab-lzsg?
Patient rarity limits volume; reimbursement negotiations can restrict pricing; competition from emerging therapies may increase.

2. How does emapalumab-lzsg compare with off-label treatments?
It offers targeted therapy with potentially better safety profiles. Off-label treatments like etoposide are non-specific and carry higher toxicity risks.

3. What is the significance of orphan drug status?
It grants market exclusivity for seven years in the U.S., priority review, and tax credits that reduce development costs.

4. Can emapalumab-lzsg be used in other diseases?
Potentially, if clinical trials show efficacy in cytokine storms, MAS, or other interferon-related conditions, expanding its market.

5. What factors could accelerate adoption of emapalumab-lzsg?
Positive clinical outcomes, expanded indications, and favorable reimbursement terms could boost sales.

References

[1] FDA. (2020). Gamifant (emapalumab-lzsg) prescribing information.
[2] IQVIA. (2022). Global biologics market report.
[3] EvaluatePharma. (2022). Top biologic drugs and market outlook.
[4] NICE. (2021). Orphan drug policies in Europe.
[5] Lifshitz, Y. T., et al. (2022). Biologic therapies in cytokine storm syndromes: a review. Journal of Clinical Immunology, 42(2), 235-245.